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Abstract 
Extracorporeal photochemotherapy (ECP), a cellular therapy involving a light activated 
drug, is FDA approved for the treatment of Cutaneous T-cell lymphoma (CTCL) and 
used for reversal of Graft-versus-Host Disease (GHVD) and solid organ transplant 
rejection.  The mechanism by which ECP functions as an immunomodulating treatment is 
unknown, although work by our lab and others suggests ECP generates functional 
Dendritic cells (DC) that may be involved in tolerization. Both radiation and 
chemotherapy have been shown to be involved in generation of tolerizing DC, and so we 
hypothesized that UVA activated chemotherapy 8-Methoxypsoralen (8MOP) exposure 
induces a tolerizing phenotype in ECP generated DC. In this study, normal donor 
peripheral blood mononuclear cells (PBMC) were treated in an in vitro model of the ECP 
apparatus, and collected (no8MOP/UVA sample) or treated with 8MOP (100ng/ml), 
UVA (2J/cm2) (8MOP/UVA sample).  We measured phenotype and functionality of 
generated cells by two-color flow cytometry and functional assays.  In all populations, we 
noted a statistically significant increase in percentage of cells staining double positive for 
DC markers (HLA-DR+/CD83+) 18 hours post treatment.  8MOP/UVA treatment 
reduced expression of mature DC markers (membrane HLA-DR/CD83) and co-
stimulatory molecules (CD80/CD86) when compared to no8MOP/UVA and positive 
control DC, and failed to stimulate CD4+Tcells in antigen presenting assay.  These data 
suggest 8MOP/UVA exposure during ECP inhibits DC maturation and induces a 
tolerizing phenotype.   These tolerizing DC may play a role in the immunosuppressive 
effects of ECP in the treatment of GVHD and solid organ transplant rejection.  
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Introduction 
Solid organ rejection and Graft-versus-host disease (GVHD) are major problems 
in clinical transplantation.  Both acute cellular and chronic solid organ rejection are 
largely mediated by T cells that use cytolytic molecules to eliminate the allograft, the 
incidence of which, varies based on procedure and on chronicity.  For instance, among 
heart transplant recipients, acute cellular rejection affects 30–50% of patients in the first 
year with 80% of heart transplant recipients surviving 10 years.  In lung transplant 
recipients, a chronic rejection syndrome, bronchiolitis obliterans syndrome (BOS), is 
expected to develop in 50% of recipients by 5 years after transplantation, and 74% by 10 
years (1). Less than 40% of lung recipients are alive 10 years after the operation.  Graft-
versus-Host Disease is a common complication of allogeneic bone marrow 
transplantation in which T cells introduced from the graft result in host tissue destruction, 
typically of the liver, skin, mucosa, and gastrointestinal tract.  The incidence of acute 
GVHD is 30-60% depending on gender and age of patient and donor if HLA matched, 
and up to 80% incidence if donor and recipient are unrelated. The incidence of chronic 
GVHD is 50%, and overall, GVHD carries approximately a 50% mortality rate (2).  
At the present time, clinical transplantation continues to rely on the use of non-
specific immunosuppressive protocols in order to prevent and treat rejection and GVHD.  
These regimens bring with them complications related to the global immunosuppression 
that they cause, such as infection and malignancies, and to toxicity related to individual 
drugs.  The most commonly prescribed drugs, such as cyclosporine and tacrolimus 
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(calcineurin phosphatase inhibitors), induce side effects such as nephrotoxicity, neuro- 
toxicity, and thrombotic microangiopathy, among many other serious complications. 
Extracorporeal Photochemotherapy 
Extracorporeal photochemotherapy (ECP) is a promising cell mediated alternative 
immunosuppressive therapy for transplant rejection, GVHD, and other T cell mediated 
autoimmune diseases, with few to no side effects.  During ECP, a patients’ leukapheresed 
blood is exposed ex vivo to an UVA activated chemotherapy agent, 8-methoxypsoralen 
(8-MOP) in a 1mm thick plastic exposure plate for twenty-to-ninety minutes.  During this 
time the 8-MOP intercalates in the DNA of nucleated cells and is cross-linked to adjacent 
pyrimidine bases by UVA light activation (3). The cross-link formation is a lethal defect 
and replicating cells are rendered apoptotic.  The processed leukocytes are then reinfused 
to the patient in a closed-loop system. (Figure 1)  
 ECP was developed in 1985 as a treatment for Cutaneous T cell lymphoma 
(CTCL), a malignancy of T cells, after it was shown to reduce cutanous disease 
involvement in 27 out of 37 patients with treatment-resistant CTCL (4). Numerous 
studies have been conducted since then (see review by Knobler (5)).  Initially believed to 
be a cytotoxic therapy, rapid clinical response in patients who had less than 10% of total 
leukocytes processed led researchers to suspect an underlying immunologic mechanism.  
ECP has since become the most widely used cell based immune therapy in the world, 
having been administered more than one point five million times (6). Approved for the 
treatment of CTCL by the Food and Drug Administration in 1988, extracorporeal 
photochemotherapy use has since been expanded to the treatment of multiple T cell 
mediated diseases with its primary use now in GVHD (60%), followed by CTCL (30%) 
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and transplant rejection (10%).  
As a treatment for CTCL, ECP is administered on two consecutive days every 
four weeks.  Although there is no standard protocol for ECP treatment in transplantation 
medicine, most studies describe a similar protocol in transplant and GVHD patients in 
which therapy begins with one to two sessions a week for four weeks and then is tapered 
depending on the clinical effect.  For instance, the median number of ECP sessions per 
patient in one particular liver transplant study was 20 (7). 
General side effects of the treatment in both adults and children are mild, 
irrespective of disease, and include malaise, low-grade fever, gastrointestinal complaints, 
as well as hypotension and syncope resulting from volume shifts during leukopheresis (8-
10). There have been some reports of side effects associated with catheter access for 
apheresis, with risk of thrombosis (11).  Notably, opportunistic infections are not 
increased by ECP treatment, suggesting antigen specific immune regulation (12).  
Solid Organ Transplant Rejection 
The use of combined psoralen and UVA (PUVA) had been implemented in 
transplant immunosuppression as early as 1985, when PUVA treatment of a kidney 
transplant in a rat model prevented rejection (13). This finding led researchers to 
investigate ECP effect in a primate model for heterotrophic heart xenotransplantion and 
allotransplantion, where animals received either ECP twice a week starting 3 days after 
transplantation, or cyclosporine and steroids.  The ECP group demonstrated absence of 
hyperacute rejection, increase in graft survival, and suppression of response in mixed 
lymphocyte reactions, as well as reversal of biopsy-proven rejection episodes in 2 cases, 
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whereas medical immunosuppression controls suffered from progressive rejection 
(14,15). 
The most compelling data illustrating ECP efficacy in solid organ transplant in 
humans would not come for many years later, and data having been generate primarily 
from retrospective studies in heart and lung transplant.  In one study involving cardiac 
transplant patients, the ECP group had a significant reduction in the number of acute 
rejection episodes, with 39% of patients having no rejection episodes, compared with 
19% among those receiving conventional therapy alone.  Furthermore, ECP did not 
increase the incidence of infection, and cytomegalovirus DNA was detected significantly 
less frequently in the photopheresis group than in the standard therapy group (16). 
Recurrent cardiac transplant rejection patients also showed reduced morbidity and 
mortality when ECP was added to conventional medical therapy (17).  
The data supporting ECP in lung transplant recipients has come from 
retrospective trials looking at halting or slowing an already progressed chronic rejection 
process BOS.   The first of such studies demonstrated histological and clinical 
improvement (improved FEV1) in patients with acute or chronic rejection (8,18,19).  
In the last 2 years, two larger accounts of ECP in lung transplantation have been 
published. The first, by Benden, reviewed their long-term experience in 24 patients. All 
patients experienced clinical stabilization and none developed BOS after completing the 
ECP protocol.  ECP was well tolerated and not associated with adverse events. The most 
recent report regarding ECP and lung transplant rejection suggests ECP slowed down the 
rate of decline in lung function in 60 patients with progressive BOS for whom they had 
data for the 6 months preceding ECP.  All studies to date have suggested that patients 
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with early-stage BOS are more likely to improve or stabilize lung function with ECP 
(20).  
Other notable case reports include ECP used in two face transplantations.  ECP 
therapy, associated with maintenance immunosuppressive therapy and doses of 
methylprednisolone, succeeded to reverse the rejection process without the development 
of other side effects or need to intensify the immunosuppressive regimen (21,22). The 
dosing of ECP in these cases was started 10 months post-transplantation.  ECP was 
performed twice a week for 4 weeks or once a week for 8 weeks and was well tolerated.  
Acute and Chronic GVHD 
The most convincing data supporting ECP’s efficacy in the treatment of acute 
GVHD in humans comes from a prospective phase II study, including 59 patients with 
either steroid-refractory or steroid dependent disease (23).  After a median of 1.3 months 
of therapy, which involved 2 consecutive days of treatment for 1-4 week intervals, 82% 
of patients with cutaneous involvement, 61% with liver involvement, and 61% with gut 
involvement achieved a complete resolution of GVHD. In this study, ECP allowed faster 
corticosteroid tapering and discontinuation in responders, reducing steroid associated 
morbidity.  Overall survival at 4 years, based on Kaplan-Meier estimates, was 
significantly higher for patients who showed a complete response to ECP, compared with 
those who did not.  The effects of ECP in patients with acute GVHD were sustainable 
and indicated that ECP might be effective as, not only a second line agent, but also a 
first-line therapy for acute GVHD.  
Several studies support ECP efficacy in chronic GVHD, particularly in regards to 
cutaneous manifestations with data suggesting 20/25 chronic GVHD patients with long-
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standing, refractory disease had skin manifestations responsive to treatment (24,25). Up 
to 80% were able to discontinue or reduce their steroid or immunosuppressive 
medications (26).  In a retrospective study involving 71 patients who had received ECP, 
the overall response rate was 61% with a CR of 20% (27). Highest responses were 
achieved in patients with chronic GVHD of the skin, liver, oral mucosa, and eye.  In 
addition, patients responding with ECP had longer survival compared with those failing 
treatment (28).  
Despite the clinical success of ECP in transplant rejection and GVHD, the exact 
mechanism by which ECP generates immunotolerization remains unclear.  ECP holds 
enormous promise as an immuno-modulating agent, not only as a supplementary 
treatment in transplant medicine, but as a possible first line therapy.  ECP has been 
shown to be efficacious and most importantly, generates a specific immunotolerizing 
effect without general immunosuppressive side effects and morbidity seen with medical 
immunosuppression.  The future of ECP in the treatment of GVHD and transplant 
rejection depends on a clear understanding of the underlying mechanism of this 
procedure in order to optimize treatment and dosing protocol.  In addition, the 
immunotolerizing effects of ECP have broad clinical application to an array of T cell 
mediated diseases.  ECP is already beginning to be investigated as an immunomodulatory 
agent in some autoimmune diseases such as rheumatoid arthritis, systemic sclerosis, SLE, 
pemphigus vulgaris, multiple sclerosis, generalized extensive lichen planus, diabetes, and 
refractory Crohn’s disease (29-32). A clear understanding of ECP’s mechanism will 
allow for expansion of treatment applications and improvement of patient care.  
Mechanism 
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There is significant evidence in animal and human models to suggest that the 
underlying mechanism of ECP in GVHD and organ transplant rejection lies in its ability 
to induce tolerance via antigen-specific regulatory T cells (CD4+CD25+FoxP3+ Tregs).  
Regulatory T cells (Treg) are a subpopulation of CD4+ lymphocytes, comprising 5% to 
10% of the peripheral blood pool that maintain immunological self-tolerance in the 
periphery.  Tregs also regulate or suppress other classes of immune response such as 
allograft rejection, allergy, tumor immunity, and responses to microbes.  These cells 
express the Foxp3 transcription factor and CD25, the high affinity interleukin-2 receptor 
(IL-2R) (33, 34) and directly suppress T-cell activation, possibly through membrane 
expression of molecules such as CTLA-4. In addition, Treg lymphocytes may mediate 
distal antigen nonspecific suppression through the secretion of cytokines such as IL-10 
and TGF-1 (35).  
In ECP treated heart and lung allograft recipients, Treg blood levels doubled 
compared to normal controls, and this increased Treg level persisted for more than a year 
after treatment (36). Similarly, in a study of lung transplant recipients, ECP was shown to 
slightly increase or stabilize the number of circulating Tregs, and this finding correlated 
with decreased organ rejection (37).  In a mouse model of heart transplantation, George et 
al. demonstrated a twofold increase in the number of splenic Tregs in ECP-treated 
animals (38).  In addition, ECP increased survival in two strains of mice, and the effect of 
ECP could be transferred to a non-ECP-treated animal via the infusion of purified Tregs. 
In a murine model of immune tolerance, Maeda et al demonstrated that transfer activity 
was lost when cells were depleted of CD4 (+) or CD25 (+) subpopulations (39, 40).  
More recently, Schmitt et al. showed that ECP stimulates the conversion of adenosine 
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triphosphate (ATP) to adenosine, a soluble immunosuppressive mediator of T cell 
activation (41).  At this point, it seems that the upregulation of Tregs in the circulation is 
at least one of the ways ECP exerts its benefit.  
How might ECP induce regulatory T cells?  The details of how ECP induces 
Tregs remain unclear, however, several hypotheses have been proposed.  The primary 
theory is that in vivo Dendritic Cell (DC), professional antigen presentation cells, are 
induced to become immunotolerizing DC secondary to processing the apoptotic cells 
delivered during ECP.  To discuss this theory further, a more detailed understanding of 
DC is required.   
In the steady state, most DCs in lymphoid organs arise from a blood precursor, 
which proliferate in the lymphoid organ, particularly the T cell areas.  Another potentially 
major source of DCs is monocytes (42). DCs are uniquely located beneath the epithelium 
at several mucosal surfaces (e.g. airway, intestine, and stomach) and these cells insinuate 
their dendritic processes between epithelial cells to enter the mucosal lumen (43, 44). The 
most intricate feature of DCs is their capacity to differentiate or mature along many 
different lines.  The general consensus is that maturity level is directly related to immune 
function. As shown in Figure 2, in the immature state, DCs have a high capacity for 
endocytosis, low MHC class I and II expression, as well as low expression of T cell co-
stimulatory molecules (CD80/CD86).  These immature DC are generally believed to be 
immune-tolerizing.  Maturing DCs express high levels of CD80/CD86, and high 
membrane MHCII, and present antigens to stimulate T cells.  Both immature and mature 
DC express CD11c, cytoplasmic HLA-DR and CD83 at comparable levels, and thus 
these molecules are considered non-specific marker for DC.  
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Maturation is driven by many different types of stimuli including microbial 
ligands for pattern recognition receptors, innate lymphocytes, immune complexes acting 
on Fc receptors, and additional environmental and endogenous stimuli, much of which 
has not been identified.  Depending on the stimulus as well as environmental factors 
affecting lymphocytes, DC then determine the type of response, which can be either 
immunogenic, providing resistance, or tolerogenic, silencing an immune response.  
One sphere of immunity that is particularly sensitive to the type of stimulus 
encountered by DCs is CD4+ helper T cell differentiation. The specific pathway followed 
by CD4+ T cells, whether it involves Th1, Th2, Th17, Tf, Tr1, or Treg cell differentiation, 
is significantly governed by DCs (42). Immature, tolerogenic DCs have been shown to 
induce the differentiation and proliferation of Regulatory T cells (Tregs) (45). Thus, 
leading to speculation that tolerizing DC generated by in vivo uptake of apoptotic 
leukocytes, one of the known stimuli for an immature DC phenotype, is responsible for 
the increase in Tregs measured in the blood of ECP-treated transplant patients.  
As mentioned previously, ECP acts by exposure of peripheral blood mononuclear 
cells to light activated drug in a thin plastic exposure plate, during which time 
lymphocytes undergo apoptosis.  Reintroduced apoptotic bodies are taken up in vivo by 
dormant Dendritic cells in the spleen and liver.  Rapid in vivo clearance of apoptotic 
bodies in the absence of danger signals (e.g. double stranded RNA, LPS, etc) has been 
demonstrated to be one of the identified stimuli that induces a tolerizing DC phenotype 
and subsequent immunosuppressive effect (46). When resident DCs engulf apoptotic 
bodies with out other danger signals they become tolerizing DC and exhibit an immature 
phenotype with low expression of costimulatory molecules, increased anti-inflammatory 
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cytokine IL10 (47) and induce antigen specific regulatory T cells.  Researchers have 
proposed that surface interactions between apoptotic cells and monocyte-derived DC via 
complement components C1q and iC3b is responsible for impairing maturation; with 
associated reduced secretion of IL-6, TNF-! and decreased T cell allo-stimulatory 
function (48).   Interaction with iC3b-opsonized apoptotic cells prevented up-regulation 
of MHC class-II Ag, CD86, CC chemokine receptor (CCR)2, CCR5, and "2 integrins, 
but increased expression of CCR7 in human DC (49). Thus, DC that uptake of iC3b-
opsonized apoptotic cells in peripheral tissues remain immature/semi-mature, but capable 
of migrating in response to CCR7 ligands to secondary lymphoid organs and initiate or 
maintain peripheral tolerance. 
There are convincing data from our lab and others suggesting the mechanism of 
ECP tolerizing action may be more complicated than simply injection of apoptotic 
lymphocytes.  In 2005, Maeda et al, created a murine model of ECP immunotolerance 
function in contact hypersensitivity.  Splenocytes and lymph node cells of mice that were 
sensitized with dinitrofluorobenzene were exposed to 8-MOP plus UVA in vitro. In an 
animal model, more than 50% of CD3+ T cells are apoptotic within 24 h after ECP 
treatment, whereas apoptosis of CD11c+ cells is slightly delayed.  Intravenous injection 
of these cells into naive mice caused inhibition of a hapten immune response, which was 
lost upon depletion of CD11c (+) cells but not T cells, suggesting that APCs directly 
generated during treatment play an essential role in ECP-induced tolerance. Mice that 
received untreated cells or cells exposed to UVA or 8-MOP alone were not affected. 
Inhibition was cell-mediated and Ag-specific as demonstrated by transfer of tolerance 
from the primary recipients into naive animals, which could, however, properly responds 
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to the unrelated hapten oxazolone. Reinfusion of ECP-treated cells without these 
preapoptotic CD11c+cells fails to induce tolerance (39).  
Previous work by our lab has shown that monocytes from ECP-treated CTCL 
patients, thought to be more resistant to apoptosis, are activated to become immature 
CD11c+, CD83, cytoplasmic HLA-DR+ dendritic cells (DC) during passage through the 
1mm plastic ultraviolet exposure plate6. This phenomenon was shown to be generalizable 
to GVHD patients as well as normal human subjects treated with in vitro ECP plate 
model.  Monocytes were analyzed by flow cytometry for the DC markers cytoplasmic 
HLA-DR, and CD83, before, immediately after and 18 hours post therapy.  Overall, after 
18 hours incubation, more than a six-fold increase in DC, over baseline, was found, with 
30 percent of the processed monocytes developing this phenotype. Importantly, this 
effect is independent of disease state and these results validated the first in vitro human 
ECP system that incorporated a plate apparatus as an appropriate model to study the 
effects of ECP treatment on DC activation.  This finding has been validated by 
microarray analysis (6). A single ECP cycle generates up to 300x106 functional DC, a 
number comparable to that generated for DC vaccines.  Based on Maeda’s work in a 
murine model, DC generated on the plate are critical for tolerization. Thus, we 
hypothesized that the DC generated on the plate during ECP played an integral role in the 
immunosuppressive activity of the therapy.  It is not so simple as apoptotic load, but the 
act of directly delivering a antigen-specific tolerizing DC therapy that is responsible for 
ECP’s underlying mechanism.  
Tolerizing DC 
In addition to uptake of apoptotic or self-antigen, research thus far has shown that 
! QM!
UVB irradiation, infection with RSV, treatment with IL10, and treatment with Mitocycin 
C (MMC), induced DC with tolerizing affects (50,51).  In several studies, irradiation of 
immature monocyte derived DC with 500-3000rads of gamma-rays have been shown to 
down regulate the expression of maturity markers (costimulatory receptors CD80/CD86 
and HLA-DR molecules) on dendritic cells, and may compromise their ability to capture 
and present antigen, while maintaining their immature DC 
migratory/phagocytotic/endocytic capacities.  The T cell proliferative response in the 
MLR and the response to tetanus antigen or LPS was reduced when gamma-irradiated 
primary DC1 were used to either stimulate or present antigen to T cells (52, 53).  DCs 
were resistant to irradiation-induced apoptosis.  IL-12 secretion by irradiated DC was 
decreased in a dose-dependent manner. 
Based on what is known regarding the factors that have been shown to prevent 
DC maturation (MMC, gamma irradiation) we hypothesized that a similar reactant, the 
UVA-radiation activated chemotherapy agent 8-methoxypsoralen (8MOP/UVA), might 
be critical in creating a tolerating DC phenotype during ECP.  Exposure of leukocytes to 
light activated drug is an important step in ECP.  Because one can control the 
concentration and degree of photoactivation, it is among the most finely titratable and 
focusable pharmacologic agents in clinical use.  The effect of 8MOP/UVA on monocyte-
to-dendritic cell activation and maturation in ECP generated DC, however, has not been 
studied in a human model to our knowledge.   
Hypothesis 
We theorized that with normal human cells treated in an ECP exposure plate 
model +8MOP/UVA would have decreased costimulatory molecules CD80/CD86 and 
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membrane MHC classII molecules, all required by maturing DC for antigen presentation, 
compared to cells passaged through the identical apparatus with out 8MOP/UVA.  In 
addition, we hypothesize that DC generated in the presence of 8MOP/UVA will not be 
able to present antigen to T cells and will have tolerizing effect.  
Specific Aims 
1. Our primary aim is to investigate the effect of 8MOP/UVA on DC maturation and 
function during ECP in order to better understand the immunomodulating effects of the 
treatment for GVHD and solid organ transplant patients.  
2. ECP has a paradoxical effect, in that it is capable of eliciting an anti-tumor response in 
the Tcell malignancy CTCL and an immunomodulating effect in GVHD and solid organ 
transplant rejection.  It is not well understood how this effect is possible.  Since we know 
that dendritic cells have the capacity to be either immunotolerizing or immunogenic, we 
hypothesize that these cells generated during ECP play a role in the paradoxical 
mechanism. The second aim of studying the effects of light activitated drug on ECP 
generated DC is to contribute further to our understanding of the seemingly complex 
immunology that underlies ECP efficacy, thus generating new hypotheses that explain 
both anti-tumor and immunosuppressive effects.  
 
Materials and Methods 
*All methods, unless otherwise noted, were performed by student 
Normal blood donors 
 In order to determine the effect of 8MOP/UVA on DC maturation in a human ex vivo 
ECP model, Peripheral blood mononuclear cells (PBMC) were isolated from 200 cc of 
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normal human donor whole blood by ficoll/hypaque separation.  Leukocytes were 
counted and pretreatment sample allocated and stained for phenotyping.  An 
Extracorporeal chemotherapy (ECP) apparatus model (shown in Figure 1) was designed 
to allow for control of UVA exposure variable and incorporated a plastic exposure plate, 
injection port, 2 collection bag sites with clamps, an attachment for normal saline, a UVA 
light source with temperature gauge and on/off switch, and a peristaltic pump.   Plate 
primed with 3:1 saline: autologous serum (from ficoll/hypaque separation) for one hour.  
PBMC resuspended in 50-100 cc RPMI were processed at 100 cc/hour for 1.5 hours. Half 
the isolate was collected from collection bag [no8MOP/UVA, (n=3)].  8MOP (100 
ng/ml) was equilibrated for 15minutes in apparatus before exposure to UVA (2J/cm2 ) 
and collected [8MOP/UVA, (n=6)]. Negative control cells (n=3) were untreated PBMCs. 
Priming, exposure time, 8MOP dose, and UVA dose estimate from original Therakos 
ECP apparatus.   Aliquots were procured immediately after procedure and stained for 
phenotyping.  
Cell Culture 
In ECP, it is not possible to examine phenotypic and functional changes in treated 
monocytes since those cells are immediately reinfused into patients. Therefore, negative 
control and treated normal donor cells were cultured for 18 hours to study induced 
monocyte maturation and function in 1 liter Baxter platelet storage bags (37°C, 5% CO2) 
in RPMI-1640 medium, 1%P/S, 10%AB serum. Following overnight culture (18hours), 
cells were harvested and either stained for flow-cytometry or underwent monocyte 
enrichment for mixed leukocyte reactions and antigen presentation assays.  Monocyte 
enrichment was achieved using Monocyte Isolation Kit II magnetic microbeads 
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(Miltenyi) Prior to and after 8- MOP/UVA exposure PBMC were depleted of CD4 T cells 
by using CD4 magnetic microbeads (Miltenyi), yielding 60-80% monocyte enrichment. 
Patient samples 
In order to test the validity of the in vitro ECP system, normal blood donors were 
compared to leukocytes from patients with CTCL or GHVD undergoing ECP using the 
UVAR XTS Photopheresis System (Therakos).  Cells were obtained under the guidelines 
of the Yale Human Investigational Review Board. Informed consent was provided 
according to the Declaration of Helsinki *(performed by others).  
Positive control monocyte derived DC (MoDC) were generated from identical 
normal donor whole blood collected one week prior to plate experiment.  Isolated 
monocytes by MAC-3 magnetic cell sorting to 5 # 106 cells/mL used for protocol 
 Immature DC were generated over 6 to 7 days, first incubated in 6 well plates RPMI 
1640 with 2.05 mM l-glutamine, and 15% ABserum, 15% patient serum with 200 ng/ml 
of GM-CSF/ml and 4 ng/ml of IL-4 /ml. Half media changed Q2-3 days with fresh 
cytokines. Induction of DC maturation with LPS (10ng/ml).    
Immunophenotyping  
5 million cells from each sample set aside for two-color flow cytometry analysis to 
determine DC immunophenotype and maturation status. Monoclonal antibodies specific 
for monocytes and DC, included: CD14 (LPS receptor, monocytes); CD36 (receptor for 
apoptotic cells, monocytes); HLA-DR (class II MHC molecule: immature DC- 
cytoplasm, mature DC-membrane); CD83 (DC marker); and CD80 and CD86 (B7.1 and 
B7.2 co-stimulatory molecules).  Antibodies were obtained from Beckman Coulter and 
used at their pre-determined optimal dilutions. Background staining was established with 
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appropriate isotype controls, and immunofluorescence was analyzed using a FC500 flow 
cytometer (Beckman Coulter). Combined membrane and cytoplasmic staining was 
performed following manufacturer’s instructions for cell fixation and permeabilization 
(Intraprep kit, Beckman Coulter).*(Calculation of total cell number based on CD83 
staining performed by others) 
Induction of Apoptosis 
 To test whether immature DC phenotype was induced directly or by uptake of apoptotic 
lymphocytes, apoptotic lymphocytes were incubated with no8MOP/UVA cells at 1:4 
ratio for 18 hours at 37C in an identical manner to other overnight cell culture previously 
described here.  Apoptosis was induced by irradiation of autologous magnetic bead 
isolated CD4+lymphocytes with a calibrated UV lamp at a dose of 2,500 mJ/cm2 at a 
density of 1 x106!cells/ml in six-well plates in RPMI or X-VIVO15 medium 
supplemented as described above.  we monitored apoptosis serially after UV irradiation 
by trypan blue staining.  
Antigen presentation assay 
Volunteer freshly isolated, magnetic bead-enriched, antigen-experienced CD4+ 
populations (2 x 106ccells/cc, 50 µl/well) were added to A) Pos control DC, B) 
no8MOP/UVA generated DC C) 8MOP/UVA DC D) combination of A and C.  DC were 
plated in flat- bottom 96 well plate at (2 x 106/cc, 50 µl/well) in the presence of tetanus 
toxoid (5,10 and 15 µg/ml, 100 µl/well) and 100 µl RPMI 1640/15% autologous serum. 
Control is responder T cells + responder T cells. CD4+ cell purity determined by flow 
cytometry. After 5 days of culture, the cells receive1 µCi [3H]- thymidine and incubate 
overnight, are harvested, and counted in a Beta liquid scintillation counter (Perkin-
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Elmer). The results are calculated by averaging the mean background counts per minute 
(CPM) from 5 samples obtained by culturing responders w/out stimulating cells and 
subtracting the CPM from the average results of the CD4 T cells responding to allogeneic 
stimulators (54).  
One-Way Mixed Leukocyte reaction 
The one-way mixed lymphocyte reaction (MLR) protocol is designed to test the 
proliferation of one individual’s lymphocytes (autologous) in response to foreign 
histocompatiblity antigens on lymphocytes from another individual (allogeneic) that have 
been irradiated to prevent them from proliferating.  Allogeneic responding CD4+ T cells 
were obtained from normal blood donor CD4-magnetic bead purification (90–95% CD4+ 
T cells). Aliquots containing 2 # 105 cells/well allogeneic stimulatory cells gamma 
irradiated (2000 rad), were co-cultured with 2 # 105 cells/well autologous CD4+ T cells 
or with out stimulator cells in 5replicate wells of round-bottomed 96-well plates with the 
addition of 100 µl/ well RPMI 1640 containing 15% AB serum and 15% autologous 
serum. After 5 days’ incubation at 37°C, 5% CO2, 1 µCi 3[H]-thymidine was added, The 
cells harvested and radioisotope uptake measured 16 hours later, using a liquid 
scintillation counter. The results were calculated by averaging the mean background 
counts per minute (CPM) obtained by culturing responders w/out stimulating cells and 
subtracting the CPM from the average results of the CD4 T cells responding to allogeneic 
stimulators (54).   
Results 
 In order to study the effects of 8MOP/UVA on DC maturation, we needed to 
construct and validate an appropriate in vitro human model that allowed for control of 
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this variable.  A model based on Therakos ECP apparatus was created that allowed for 
cells to pass through the plate in the absence or presence of the light with out significant 
difference in plate exposure time.  Temperature was determined to be stable at room 
temperature throughout in vitro treatment.  To validate our experimental model, normal 
donor PBMCs (n=6) were processed with the ex-vivo apparatus and compared to 
leukopheresis from CTCL patients (n=3) and GVHD patients (n=3) treated with Therakos 
ECP from a prior study, using CD83/HLA-DR coexpression as a measure for monocyte-
to-DC conversion. As shown in Figure 3a, we noted a statistically significant increase in 
percentage of cells staining double positive for DC markers (HLA-DR+/CD83+) 18 
hours post-ECP treatment in all population.  The difference between mean pretreatment 
(4%) and immediately post-treatment (2%) co-expression of CD83/HLA-DR was not 
statistically significant.  However, 18 hour incubation produced an average of 30%+/- 8% 
monocyte-to-DC conversion, more than 7-fold increase in the expression of this standard 
DC marker over background levels, (p<0.001). There was no significant difference in 
CD83/HLA-DR expression between patient and normal blood donor samples treated with 
experimental model at 18hr incubation time point. The last set of bars demonstrates the 
mean and standard deviation for all twelve subjects. 
 The absolute number of ECP-processed monocytes that expressed this DC 
phenotype after overnight incubation was assessed in cells from 6 patients and 3 normal 
subjects using CD83 positivity as the criterion.  The DC yield, one day after ECP 
processing of monocytes from normal subjects (54 -316 x 106), compares favorably to 
that produced after conventional 5-6 day maturation of leukapheresed human 
mononuclear cells cultured in GM-CSF/IL4. 
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 To determine whether 8MOP/UVA exposure was required for monocyte-to-
dendritic cell conversion during extracorporeal photochemotherapy, we processed 
autologous human leukocytes from normal volunteers (n=3) in the in vitro ECP apparatus 
in the presence (8MOP (100ng/ml) + 2J/cm2 UVA (8MOP/UVA)) or absence of 
8MOP/UVA with equal plate exposure time of 1.5 hours. We assessed monocyte-to-
dendritic cell conversion by measuring coexpression of cytoplasmic CD83 and HLA-DR, 
dendritic cell markers, using two-color flow cytometry.  Negative control cells were not 
exposed to plate and positive control cells were MoDC (cultured with IL4/GM-CSF for 7 
days and matured with LPS 10ng/ml).  Figure 4 suggests there was no significant 
difference in percentage of CD11c+CD83+HLA-DR+ cells after 18 hr incubation 
between positive control DC (47.33% +/-13.69), no8MOP/UVA treatment (36%+/-8.29), 
and 8MOP/UVA treatment (32.9% +/-6.86). The mean percentage of CD14+/CD11c+ 
cells positive for CD83+/HLA-DR+ (34.45%+/- 7.01) for all 6 experimental subjects 
after 18 hr incubation compared to pre-treatment (0.78%+/-0.51; p<0.001).  There was no 
significant change in CD83+/HLA-DR+ coexpression after 18hr incubation in negative 
control samples, PBMCs not exposed to ECP apparatus (4.83 +/- 2.91 vs 11.47 +/- 4.65, 
p=0.12). 
 The costimulatory markers CD80/CD86 are required for antigen presentation and 
have the level of expression has been associated with dendritic cell maturity; with low 
levels of expression suggesting immature, tolerizing DC and high expression associated 
with mature, immunogenic dendritic cells (Figure 2). Therefore, to test our hyptothesis 
that 8MOP/UVA exposure prevents maturation of DC during ECP, we measured 
CD80/CD86 levels in the presence and absence of light activated drug before treatment, 
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immediately after, and 18hours incubation after treatment. Figure 5a represents a sample 
of a minimum of 3 experiments and suggests 8MOP/UVA reduces DC costimulatory 
molecule (CD80/CD86) expression (4.2%) compared to no8MOP/UVA population 
(29.5%). Figure 5b shows the means, where 8MOP/UVA decreased CD80/CD86 
coexpression 7-fold on average (8MOP/UVA: 4.1+/-3.6 vs no8MOP/UVA: 27.5 +/-5.40) 
and was highly significant, p<0.000001. Mean expression CD80/CD86 in 8MOP/UVA 
DC (4.1%+/-3.62) was not significantly different from pretreatment value (2.38%+/-3.00, 
p=0.43).  We found 76.73%+/-8.75 of positive control mature DC (generated by 
traditional 7-day IL4/GM-CSF tissue culture and matured with LPS) to express both 
CD80 and CD86, while pretreatment PBMC did not express either of these mature DC 
molecules as expected (2.38+/-3.00).  
 To test whether the decrease in costimulatory molecules might be associated with 
apoptotic body uptake, no8MOP/UVA generated cells were incubated for 18hours at 4:1 
ratio with apoptotic CD4+cells and analyzed by two-color flow cytometry for mature DC 
markers CD80/CD86.  As shown in Figure 5b, addition of apoptotic CD4+ lymphocytes 
decreases CD80/CD86 expression on no8MOP/UVA DC population. Addition of 
apoptotic cells resulted in a small, but statistically significant, decrease in costimulatory 
molecule expression compared to the no8MOP/UVA DC (19.25%+/-4.75 vs. 27.5+/- 
5.40, p=0.033).  
Another set of mature DC markers, membrane HLA-DR and CD83 on the 
membrane were also reduced on 8MOP/UVA-exposed cells (Figure 5c).  Negative 
control cells were PBMC incubated for 18hrs. Positive control DC were generated by 
traditional 7 day IL4/GM-CSF tissue culture and matured with LPS.  Experiments were 
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repeated a minimum of 3times. The difference in double positive membrane CD83/HLA-
DR expression after 18hr incubation between no8MOP (16.7+/-2.62) and negative 
control (5.05+/-1.50) is highly significant (p<0.00001) and did not differ from positive 
control Monocyte derived DC (MoDC) matured with LPS (20%+/-1.62). There was no 
statistical difference between 8MOP treatment group (5.38% +/- 1.45) and negative 
control (5.05+/-1.50).  
Mature APCs elicit an antigen specific immunogenic response by presenting 
antigen to syngeneic CD4+ Tcells on HLA receptors.  We tested our hypothesis that 
8MOP/UVA prevented DC maturation and thus antigen presentation capabilities, by 
testing the cells generated overnight in antigen presenting assays. Figure 6a suggests that 
8MOP/UVA treated, immature DC (green) are not capable of stimulating antigen-specific 
CD4 cells.  The red line and dark blue line represents vigorous CD4 stimulation by 
no8MOP DC and Pos Co DC (IL4/GMCSF generated DC respectively, and is antigen 
dose dependent.  Most significantly, when 8MOP/UVA DC were added as a third party to 
the pos Co reaction (blue) these DC actively suppressed the T cell response to the antigen 
(purple).   
In addition, 8MOP/UVA DC were less efficient at stimulating allogeneic CD4+ 
cells in a one-way mixed leaukocyte reaction when compared to control stimulator cells 
(Figure 6b).  The gamma irradiated stimulator control was significantly more efficient at 
stimulating CD4+ response than 8MOP/UVA treated cells (13.2x103 +/-5x103 vs. 6.0 
x103 CPM+/-5x103, p<0.0001). An autologous CD4+ cell reaction was used as a negative 
control (responder +responder). Results are the mean and standard deviated of 5 replicate 
wells of a minimum of three experiments.  
! SM!
Discussion 
The purpose of this study was to further elucidate the immunotolerizing mechanism of 
ECP in the treatment of GVHD and organ transplant rejection.  Clinical and laboratory 
data suggest that ECP’s immunoregulaory effect is mediated by tolerizing DC and Tregs, 
although the details of how ECP mediates this cellular effect were unclear.  
Dendritic Cell Immunotherapy   
Previous studies from our laboratory suggest that passage of normal human donor 
monocytes or patient cells through the 1mm ECP plate induces monocyte-to-dendritic 
cell conversion in a single day.  DC identity was assessed by flow-cytometry analysis of 
dendritic cell markers and microarray data (6) is a significant finding, since the 
conventional approach for generating dendritic cells involves in vitro tissue culture with 
supra-pharmacologic concentrations of cytokines over the course of a week.   Both 
processes generate cells in equal amounts, in the order of 54-316 x106 total cell number 
of functional dendritic cells, which can be reinfused to the patient (6, 55). 
 Using the human tabletop in vitro model of ECP, we were able to investigate the 
role of light activated drug in this important cellular immunotherapy.  Findings from this 
study suggest that monocyte-to-dendritic cell differentiation during ECP occurs in the 
absence of 8MOP/UVA and thus, in the absence of any apoptotic cells or other antigen.  
It is the passage through the plate and/or incubation overnight that is required for 
expression of dendritic cell antigens, and these DC go on to mature and present antigen to 
T cells.  Notably, this phenomenon is disease independent.  Research into the mechanism 
of monocyte-to-DC differentiation during ECP is on going in our lab and data suggests 
interaction of plastic surface and platelets with monocytes, and activation of the 
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chemokine/adhesion pathway is critical for dendritic cell activation. in ECP-processed 
monocytes from CTCL, GVHD and normal subjects (56). 
 Importantly, Dendritic cell therapy has been advancing and is now most clinically 
relevant in oncology for the treatment of multiple cancers.  Long-term survival has been 
demonstrated in the treatment of renal cell carcinoma with pulsed dendritic cells (57) as 
well as mesothelioma (58).  INGN-225, a p53 modified DC vaccine has improved 
immune response in small cell lung cancer, and sensitizes the cancer cells to 
chemotherapy (59). There are studies ongoing testing DC vaccines in pancreatic cancer 
and glioblastoma multiforme, with anti-CD25 monoclonal antibody for treatment of stage 
III and IV melanoma, breast cancer, and prostate cancer (60-64). The potential for DC 
generated from monocytes not exposed to 8MOP/UVA as dendritic cell therapies is 
endless. In this study, we show these cells to be functional, antigen presenting, allogeneic 
to a patient, and can be generated in a single day.  With future research, it could be 
feasible to passage a patient’s PBMC’s through the plastic plate with out 8MOP/UVA 
and with the addition of any antigen and proper costimulation create an allogeneic 
Dendritic cell anti-tumor therapy in a single day, that could be reinfused back to the 
patient. 
Immature DC 
 In addressing our hypothesis that 8MOP/UVA impedes maturation of DC during 
ECP, we measured several known markers of DC.  Notably, general DC markers CD83, 
cytoplasmic HLA-DR, were not significantly different among +8MOP/UVA and 
no8MOP/UVA cell populations.   This suggests that both groups underwent monocyte to 
immature DC conversion, and the 8MOP/UVA cells were not frozen as monocytes or no 
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longer living.  Molecules required for DC to function as mature APCs, costimulatory 
molecules CD80/CD86 and membrane MHCII HLA-DR was significantly reduced in the 
8MOP/UVA cell population compared to those cells that received no drug/light exposure.  
These data indicate that 8-MOP does in fact impede the maturation of the exposed DC. 
 In a tetanus toxoid antigen recall assay, 8MOP/UVA treated immature DC and 
were not capable of stimulating antigen-specific CD4 cells, and most significantly, 
appear to actively suppress the T cell responses to this recall antigen when added as a 
third party to a positive response generated by Positive Control DC .  The background of 
CD4+ cells + stimulators with out tetanus toxoid is likely secondary to human autologous 
lymphocyte reaction (AMLR), proliferation of T-cells to signals from autologous non-T 
cells (65). 8MOP/UVA DC were also less effective than control allogeneic stimulator 
cells at generating a T cell response in a one-way mixed leukocyte reaction. This result is 
consistent with our previous observations, since 8MOP/UVA DC expressed fewer class II 
MHC molecules and costimulatory molecules on their surface than non-treated cells. 
The phenotypic and functional studies together suggest that 8-MOP/UVA DC are 
immune-tolerizing, and may be actively inhibitory of antigen presentation to T cells, 
either directly or indirectly.  These results are consistent with ECP’s immunotolerizing 
effect in the treatment of GVHD and solid organ transplant rejection, and support our 
hypothesis that the immature DC generated on the ECP plate are the active cells involved 
in the treatment mechanism.  
Since the previous prevailing theory of ECP mechanism is that uptake of in vivo 
apoptotic bodies by splenic DC induces immune tolerization, we examined the effect of 
apoptotic bodies in vitro combination with our ECP generated DC. Research has 
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suggested that apoptotic cells produce anti-inflammatory cytokines, such as IL-10 or 
TGF-beta, an anti-inflammatory environment that stimulates immature dendritic cells to 
engulf the apoptotic cells, which then produced immunoregulatory cytokines (IL-10 or 
TGF-beta) and decrease their production of pro-inflammatory cytokines (e.g., TNF-alpha, 
IL-1, or IL-12).  DC that engulf apoptotic bodies down regulate costimulatory molecules 
and activate regulatory T cells downstream.   We hypothesized that the DC generated on 
the plate during ECP might be engulfing apoptotic allogeneic lymphocytes sensitive to 
8MOP/UVA with down-stream immune tolerizing effects.   To test this, we incubated 
apoptotic allogeneic CD4+ lymphocytes with no8MOP/UVA population (ratio 1:4) for 
18hours and analyzed these cells for markers of DC maturation. We noted a decrease in 
expression of costimulatory molecules that was statistically significant, but not as striking 
as the effects of direct 8MOP/UVA exposure on PBMCs during ECP.  Future studies will 
examine dose response of this phenomenon.  
There is some data in the literature, however, to suggest that apoptotic body 
uptake by DC does not explain or is insufficient to induce an immature phenotype. First, 
in a model involving passing human leukocytes through a column with apoptotic cells, 
the apoptotic bodies have not induced immunotolerizing phenotype.  Instead, these cells 
exhibited properties of increased immunogenicity.  In addition, other furocoumarins other 
than 8-methoxypsoralen, 4,6,4$-trimethylangelicin, 4,8,5$-trimethylpsoralen, 1,4,6,8-
tetramethyl-2H-furo[2,3-h]-quinolinone, and 5-methoxypsoralen fail to induce immune 
suppression and cannot be used for ECP.  4,6,4$-Trimethylangelicin has greater 
proapoptotic effects in vitro than 8-MOP, but does not induce immunosuppression in an 
animal model of ECP.  These data combined suggests that uptake of apoptotic bodies or 
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self antigens in the absence of danger signals does not adequately explain the 
immunotolerizing phenotype of the 8MOP/UVA treated cells generated in our ECP plate 
model (5).  
An alternative hypothesis is that 8MOP/UVA is eliciting a downstream immune 
tolerizing effect via a similar mechanism to that of Mitocycin C (MMC), gamma 
irradiation, or viral infection; by directly effecting DC gene and protein expression.  
Studies testing the effect of MMC on dendritic cells, suggests MMC enhances expression 
of GILZ, a transcription factor coded by the TSC22D3 gene, which inhibits NF%B 
transcriptional activity. GILZ determines the decision of DCs regarding whether to 
stimulate or suppress the T-lymphocyte response (66). As suggested by its name, the 
GILZ gene is upregulated by glucocorticoids, but also by other agents known to convert 
DCs into tolerizing DCs such as interleukin (IL)-10 or transforming growth factor-".  
GILZ-expressing antigen-presenting cells upregulate inhibitory IL-10,molecules and 
downregulate costimulatory molecules CD80 and CD86 (66). When CD4+ T 
lymphocytes are stimulated with GILZ-expressing DCs, they develop Treg properties 
inhibiting the antigen-specific responses of CD4+ and CD8+ cells (67). Future studies 
could investigate the appealing possibility that 8MOP/UVA is an additional upregulator 
of the gene GILZ, which would explain downstream effects on T cell differentiation.  It is 
critical to differentiate between indirect (via uptake of apoptotic bodies) and direct 
(change in gene expression) control of DC maturation in the future so that these variables 
can be appropriately modulated as needed for patient treatment.  
Just as antigen-specific immunogenic DC have many implications for the 
treatment of cancer in the form of vaccinations, self-antigen specific immune tolerizing 
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human DC generated by ECP have broad implications for the treatment and prevention of 
many T cell mediated autoimmune diseases.  In this study, we have demonstrated that 
light activated drug exposure freezes ECP generated DC in an immature state and 
prevents antigen presentation activity to T-cells in normal blood donors.  These cells can 
be generated in a single 18 hour period, far less time than the typical 7 day cell culture for 
DC used in vaccinations today.  Multiple studies already discussed have demonstrated the 
efficacy of this cell therapy in the treatment of GVHD and transplant rejection, as well as 
the improved safety profile of this treatment over present medical immunosuppressant.  
Based on this study, the amount of drug and light would have a direct effect the immune 
tolerizing capacity of the dendritic cells generated during therapy.  Thus, these particular 
variables could be manipulated to improve clinical outcomes in the treatment of GVHD 
and transplant rejection.  ECP treated leukocytes should be investigated in any disease 
process that would benefit from antigen-specific tolerizing DC with downstream 
regulatory T cell activity.   
Mechanistic conundrum 
ECP has a paradoxical effect in that it is capable of eliciting an anti-tumor 
response in the Tcell malignancy CTCL and an immunomodulating effect in GVHD and 
solid organ transplant rejection.  ECP’s immune tolerizing effect and proposed 
mechanism has been discussed in detail in this report.  Data to support ECP eliciting an 
anti-tumor immune response has be described by many investigators, who report that in 
Sezary patients, clinical and haematological improvement after ECP are associated with a 
shift in Th1/Th2 balance and the increase of Th1 cytokines and IL12 as well as cytotoxic 
CD8 cells (68). Thus ECP can enhance an anti-tumoral response by Th1 type specific 
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immune response.  Additional research, however, has suggested a significant and 
sustained increase in regulatory T cells during treatment of CTCL with ECP (69). How is 
it possible for a single treatment to elicit both an antigenic response in cancer and a 
tolerizing response in GVHD and transplant rejection?  One appealing hypothesis 
proposed for future investigation is that the amount or degree of 8MOP/UVA dictates the 
immune response during ECP.  
Using our in vitro ECP model that allowed for control of UVA light exposure, we 
were able to generate two separate DC populations: one mature and immunogenic and 
one immature and immune tolerizing.  Since UVA and 8MOP exposure can vary based 
on flow dynamics within the plate, as well as individuals hematocrit, we aim to 
investigate the hypothesis that two populations of DC are generated during ECP based on 
light and drug exposure.   
Already referenced in this report, Maeda et al found CD11c+ cells generated 
during ECP to be critical to inhibition of a hapten immune response in a murine model of 
contact hypersensitivity, suggesting photopheresis exerts its primary immunomodulatory 
effect via tolerizing DC derived from ECP processed monocytes, with secondary 
induction of Ag-specific regulatory T cells (39).  In this study, we discovered the immune 
tolerizing DC are the direct or indirect result of 8MOP/UVA exposure during the 
procedure. Whereas it has been hypothesized that immature DC are induced in vivo after 
ECP treatment, this is the first reporting to our knowledge, demonstrating immature DC 
converted directly from ECP treated peripheral blood monocytes.  In the absence of 
8MOP/UVA, monocyte-to-DC conversion still occurs and these cells progress to 
maturity.  Our future studies will investigate the downstream affect on 
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Foxp3+CD25+CD4+ Tregulatory cell expression as well as immune tolerizing cytokines 
such as IL10.  These results provide important insight into the role of ECP as a current 
and future immunosuppressive treatment for GVHD and solid organ transplant rejection 
patients.  
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Figure 1. Extracorporeal Photochemotherapy (ECP). During ECP, a patients’ 
leukapheresed blood is exposed ex vivo to an UVA activated chemotherapy agent, 8-
methoxypsoralen (8-MOP) in a 1mm thick plastic exposure plate.  Upon UVA exposure, 
8-MOP intercalates in the DNA of nucleated cells and induces apoptotic in lymphocyte 
population.  The processed leukocytes are then reinfused to the patient in a closed-loop 
system.  
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Figure 2. Relationship of Monocyte Derived Dendritic Cell Function to Maturation.  
Immature DC express low levels of co-stimulatory molecules CD80 and CD86 and are 
immune tolerizing.  Mature DC are antigen presenting, immunogenic and express high 
levels of CD80/CD86. Cytoplasmic HLA-DR and CD83 is non-specific marker for DC, 
while mature DC express these molecules on their membranes.  
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Figure 3a.  Monocyte-to-DC conversion during ECP is generalizable phenomenon. 
Two-color flow cytometry analysis of 10,000 monocytes from 3 CTCL and 3 GVHD 
patients, as well as from 6 normal subjects, is shown at the three time points: from the 
leukapheresis harvest prior to ECP (Pre-ECP), immediately after ECP (ECP-Time 0 hr), 
and 18 hr after treatment (ECP-Time 18 hr) The monocyte/DC population 
(CD14+/CD11c+) was gated using forward and side scatter.  The CD83 percentage was 
obtained by staining for fixed membrane expression of class II and permeabilized 
cytoplasmic staining of CD83 (immature DC). The last set of bars demonstrates the mean 
30%+/- 8.0 for all twelve subjects, revealing significant enhancement in HLA-DR/CD83 
expression after 18 hr incubation (p<0.001), compared to pre- and immediately post-ECP.  
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Figure 3b. Absolute number of DC generated by ECP in CTCL, GVHD, and normal 
blood donors. The absolute number of DC was calculated as the product of the percent 
of leukocytes cytometrically gating, by forward and side scatter, in the Monocyte/DC 
region and the total number of cells in that region displaying the CD14 or CD11c marker 
typical of monocytes and DC. The absolute number of induced CD83+ cells varied with 
white blood cell count of the subject, but exceeded 50 million in all but one CTCL patient 
and exceeded 300 million in one normal subject. The absolute number of DC was then 
calculated by multiplying the CD83+ percentage by the relevant total volume. 
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Figure 4. CD83/HLA-DR upregulation occur independent of 8MOP/UVA. PBMC 
ficoll-hypaque isolated from normal donors were treated with in vitro ECP apparatus, and 
collected (no8MOP/UVA) or exposed to 8MOP (100ng/ml) + 2J/cm2 UVA 
(8MOP/UVA) and analyzed by two-color flow cytometry for CD83/HLA-DR 
coexpression at time 0 and time 18hrs. The mean percentage of CD14+/CD11c+ cells 
positive for CD83+/HLA-DR+ (34.45%+/- 7.01) for all 6 experimental subjects after 18 
hr incubation compared to pre-treatment (0.78%+/-0.51; p<0.001).  There was no 
significant difference in percentage of CD11c+CD83+HLA-DR+ cells after 18 hr 
incubation between positive control DC generated from monocyte tissue culture with 
IL4/GM-CSF for 7 days (47.33% +/-13.69), no8MOP/UVA treatment (36%+/-8.29), and 
8MOP/UVA treatment (32.9% +/-6.86).  There was no significant change in 
CD83+/HLA-DR+ coexpression after 18hr incubation in negative control samples, 
PBMCs not exposed to ECP apparatus (4.83 +/- 2.91 vs. 11.47 +/- 4.65, p=0.12). 
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Figure 5a. 8MOP reduces expression of co-stimulatory molecules in normal 
subjects. Forward and side scatter gating, confirmed by CD11c and CD14 staining, was 
used to identify the monocyte population. Two-color membrane staining for CD80 
(FITC) and CD86 (PE) was used to identify expression of co-stimulatory molecules on 
pos control DC (generated by traditional 7 day IL4/GM-CSF tissue culture and matured 
with LPS), pretreatment PBMC, and PBMC exposed to in vitro ECP apparatus in the 
presence (8MOP/UVA) or absence of 8MOP/UVA (no8MOP/UVA). 8MOP/UVA 
decreased CD80/CD86 coexpression 7-fold on average (8MOP/UVA: 4.1+/-3.6 vs. 
no8MOP/UVA: 27.5 +/-5.40) and was highly significant, p<0.000001.  Selected image is 
demonstrative of a minimum of 3 experiments.  
! UU!
 
Figure 5 
!"#$
#$
"#$
%#$
&#$
'#$
(#$
)#$
*#$
+#$
,#$
-./0./102/30$ -45$6430.47$ +89:;<=>$ 34+89:;<=>$ 34+89:;<=>$?$1-4-$
@A'?$'B"$
!"
#$
"%
&'
("
)*
+,
-.
/"
)0
1
23
40
1
25
)
C-D#E#&&$CC-F#E####"$
6)
GHIJ./$($
 
Figure 5b.  Addition of apoptotic CD4+ lymphocytes decreases CD80/CD86 
expression on no8MOP/UVA DC population.  No8MOP/UVA generated cells were 
incubated for 18hours at 4:1 ratio with apoptotic CD4+cells and analyzed by two-color 
flow cytometry for mature DC markers CD80/CD86.  Addition of apoptotic cells resulted 
in a small, but statistically significant, decrease in costimulatory molecule expression 
compared to the no8MOP/UVA DC (19.25%+/-4.75 vs. 27.5+/- 5.40, p=0.033).  Mean 
expression CD80/CD86 in 8MOP/UVA DC (4.1%+/-3.62) was not significantly different 
from pretreatment value (2.38%+/-3.00, p=0.43).  
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Figure 5c. 8MOP/UVA exposure decreases mature DC markers, membrane 
CD83/HLA-DR class II MHC, expression in normal subjects.  Membrane HLA-DR 
(FITC) and CD83 (PE) on the membrane were used to identify maturing DC. Negative 
control (neg control) cells were PBMC incubated for 18hrs. Positive control (pos control) 
DC were generated by traditional 7 day IL4/GM-CSF tissue culture and matured with 
LPS.  Experiments were repeated a minimum of 3times. The difference in double positive 
membrane CD83/HLA-DR expression after 18hr incubation between no8MOP and Neg 
Co is highly significant (p<0.00001) and these cells did not differ from Pos Co DC. There 
was no statistical difference between 8MOP treatment group and Neg Co.  
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Figure 6a. No8MOP/UVA DC efficiently processed and presented tetanus toxoid 
antigen to responsive autologous CD4 T cells, while 8MOP/UVA DC may repress 
CD4 T cell stimulation. No8MOP DC (red) from a tetanus-immunized normal subject, 
efficiently processed and presented tetanus toxoid antigen to fresh autologous magnetic 
bead-purified CD4 T cells, and this response was comparable to Pos Co DC (blue) 
generated by cytokine tissue culture/matured with LPS and this response was tetanus 
toxoid dose dependent.  8MOP/UVA DC (green) did not elicit a T cell response to 
increasing doses of tetanus toxoid, and when these cells were added to Pos Co reactions 
(purple), appeared to repress the response. Autologous CD4 T cells alone or the DC alone 
yielded limited or no response. Data shown are the mean and standard deviation of 3 
replicate wells of a minimum of 3 experiments.  
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Figure 6b. 8MOP/UVA reduces allogeneic CD4+ stimulation in one-way Mixed 
leukocyte reaction.  Magnetic bead-enriched CD4+ cells (responder) were added to 
allogeneic stimulator cell populations: either 8MOP/UVA treated PBMCs (8MOP) or 
gamma irradiated control cells (stimulator).  The stimulator control was significantly 
more efficient at stimulating CD4+ response than 8MOP/UVA treated cells (13.2x103 +/-
5x103) vs. 6.0 x103 CPM+/-5x103, p<0.0001). A syngeneic CD4+ cell reaction was used 
as a negative control (responder +responder). Results are the mean and standard deviated 
of 5 replicate wells of a minimum of three experiments. !
 
